The Chemagic Viral DNA/RNA kit was evaluated for extraction of cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis G virus (HGV) by using the QIAamp DNA Blood Mini kit and the QIAamp Viral RNA Mini kit as reference protocols. The extraction efficiencies of the different kits for CMV DNA and HBV DNA were not distinguishable, but the extraction efficiency for HGV RNA was better with the Chemagen protocol. All clinical specimens tested HBV DNA-or HGV RNA-positive after QIAGEN protocols for extraction were confirmed by using the Chemagen protocol. The Chemagen kit failed to confirm one of 75 CMV DNA-positive specimens. Thus, a new competitive extraction method using a technology with a high potential for automation is available.
Combining sensitive detection and quantification of pathogen-encoded nucleic acids with short processing times, nucleicacid amplification protocols are becoming a dominating technique in the diagnostic laboratory. Prerequisite to benefiting from the advantages of this technique are efficient protocols for extraction of nucleic acids. Many existing protocols are labor intensive, time consuming, or restricted to certain specimens or types of nucleic acids. The optimal protocol should offer high sensitivity for extraction of DNA and RNA from a broad range of specimens combined with low time consumption, reduced hands-on time, low price, and the potential for automation. Many procedures available so far use a precipitation step to gain pure nucleic acids from the extracts. Other protocols take advantage of the nucleic acid-binding potential of matrix material supplied in a column (1) . A recent development is the coverage of magnetic beads with nucleic acidbinding matrices, which promises a high potential for automation (5) .
In this study, we investigated the suitability of the recently released Chemagic Viral DNA/RNA kit (Chemagen, Baesweiler, Germany), which is available worldwide, to isolate viral DNA (for CMV and HBV) and viral RNA (for HGV) from human specimens for sensitive detection of viral genomes by HBV-specific, CMV-specific, and HGV-specific PCR.
One hundred ninety-two specimens tested DNA-or RNApositive for the respective pathogen (for HBV, 100 serum samples; for CMV, 8 urine samples, 52 serum samples, and 15 plasma samples; for HGV, 17 serum samples) by virus-specific quantitative PCR (HBV [Cobas Amplicor; Roche Diagnostics, Basel, Switzerland] and CMV) (6) or qualitative PCR (HGV) in our routine diagnostic laboratory following extraction with the QIAamp DNA Blood Mini kit or the QIAamp Viral RNA Mini kit (QIAGEN, Hilden, Germany). Extraction capacity was evaluated for HBV with a dilution series of the EURO-HEP standard (4 ϫ 10 5 to 1 ϫ 10 1 copies per ml of serum), for CMV with a dilution series of the standard plasmid pCR-gpB diluted in serum (2 ϫ 10 5 to 2 ϫ 10 2 copies per ml of serum), and for HGV with a dilution series of viral RNA from serum samples from a highly viremic patient (dilutions of 1 Ϫ6 to 10 Ϫ6 ). The serum for the dilution series tested CMV-, HBV-, and HGV-negative by virus-specific PCR.
Total DNA and total RNA were extracted by using magnetic bead technology with the Chemagic Viral DNA/RNA kit according to the manufacturer's recommendations. Briefly, samples (200-l) were incubated with protease and lysis buffer. Magnetic beads were added to the mixture. After incubation, nucleic acids bound to the beads were separated with a magnetic separator. After two washing steps, the nucleic acids were eluted in a volume of 50 l of elution buffer and the magnetic beads were separated from the solution. The approximate processing time for 24 samples is 100 min. As reference protocols, the QIAamp DNA Blood Mini kit was used for extraction of DNA and the QIAamp Viral RNA Mini kit was used for extraction of RNA from 200-l samples as recommended by the manufacturer. The extracted nucleic acids were resuspended in a volume of 50 l of aqua bidest. The approximate processing time for 24 samples is 100 min.
A fluorescence resonance energy transfer (FRET)-based CMV DNA amplification protocol with a sensitivity of 200 genome equivalents per ml of sample was used for detection of CMV genomes in 5 l of extracted nucleic acids (6) . Such a real-time approach allows detection of amplicons by FRET with a virus-specific primer pair labeled with fluorescent dyes. It can define the cycle number of the entry into the exponential phase of PCR and use it for quantification (2, 4) . HBV detec-tion was performed with an aliquot of 10 l of extracted nucleic acid by nested PCR on a Geneamp 9700 (Perkin-Elmer) as described elsewhere (3). The detection limit is 40 genome equivalents per ml of serum. HGV detection was performed by reverse transcription (RT)-PCR on a Geneamp 9700 with the Titan OneTube RT-PCR system (Roche Biochemicals, Mannheim, Germany) as recommended by the manufacturer. Four microliters of HGV-specific primers from the hepatitis G virusprimer and capture probe set (Roche Biochemicals) and 10 l of extracted RNA were added to the mix. The experimental PCR protocol was as follows: an initial 50 min at 30°C and 2 min at 68°C for RT, followed by 40 cycles of 45 s of denaturation at 94°C, 1 min of annealing at 55°C, and 1 min of extension at 68°C. The detection limit is 400 genome equivalents per ml of serum.
For evaluation of the analytical sensitivity of the Chemagic Viral DNA/RNA kit, nucleic acids were extracted from serum dilution series containing the CMV-, HBV-, and HGV-positive controls and subsequently amplified with virus-specific protocols. The identical samples were extracted with the QIAamp DNA Blood Mini kit (for CMV and HBV samples) and the QIAamp Viral RNA Mini kit (for HGV samples) as reference protocols. Each extraction was done at least in triplicate; all results were in agreement.
Extracts of all samples of the CMV-positive control dilution series obtained with the Chemagen and QIAGEN kits resulted in the amplification of PCR products, indicating the successful extraction of 2 ϫ 10 2 to 2 ϫ 10 5 copies per ml of serum (Fig.  1) . Quantification results following extraction with both protocols differed less than 1.4-fold (0.5 cycles) for each serial dilution. Amplification reactions using extracts of the HBVpositive control resulted in detectable PCR products for 4 ϫ 10 1 to 2 ϫ 10 5 genome equivalents per ml of serum independently of the extraction protocol (Fig. 2) . Thus, no difference in extraction efficiency could be observed between the two protocols for the extraction of HBV DNA or CMV DNA on the basis of identical sample volumes. Extracts of the dilution series of viral RNA from serum samples from a highly viremic HGV genome-positive patient obtained with the Chemagic DNA/RNA kit resulted in the amplification of PCR products, including a dilution of 10 Ϫ4 (Fig. 3) . The extraction efficiency of the QIAamp Viral RNA Mini kit was 10-fold lower.
The clinical sensitivity of the Chemagic DNA/RNA kit was (Table 1) have been analyzed. All of them resulted in a positive PCR following extraction with the QIAamp DNA Blood Mini kit. Apart from one sample previously quantified to contain 7 ϫ 10 2 copies of CMV per ml of serum, PCR products could be obtained in the remaining 74 specimens following extraction with the Chemagic DNA/RNA kit. The entire set of 100 HBV-positive sera ranging from 5 ϫ 10 1 to 9 ϫ 10 7 copies per ml of serum resulted in HBV-specific PCR products after amplification of extracts generated with both the Chemagic DNA/RNA kit and the QIAamp DNA Blood Mini kit (Table 2) . Following extraction of 17 HGV genome-positive sera with the Chemagic DNA/RNA kit, HGV-specific PCR products could be generated from all specimens. Identical results were obtained after extraction of the identical specimens with the QIAamp Viral RNA Mini kit.
We performed an evaluation of the Chemagic DNA/RNA kit by comparing the analytical and clinical sensitivity of the protocol to that of the QIAamp DNA Blood Mini kit and the QIAamp Viral RNA Mini kit. Determination of the extraction efficiency for CMV DNA, HBV DNA, and HGV RNA was done by PCR assays of standard dilution series and of clinical specimens, including serum, plasma, and urine samples. However, due to the limited numbers of urine and plasma samples used in this study, a well-grounded evaluation of the kit for extraction of nucleic acids from our data can be done only for serum.
Analysis of the nucleic acid extracts obtained by the extraction systems in use resulted in 100% detection of positive samples by the extraction systems of both companies for HBVand HGV genome-positive specimens. Analysis of the CMV genome-positive specimens detected CMV in 98.7% of the samples after extraction with the Chemagic DNA/RNA kit and in 100% of the samples after extraction with the QIAamp DNA Blood Mini kit. Evaluation of analytical sensitivity revealed identical results for CMV and HBV with both extraction systems. Extraction with the Chemagic DNA/RNA kit was 10-fold more sensitive for HGV-positive sera than with the QIAamp Viral RNA Mini kit. An advantage of both protocols is the absence of a precipitation step, which often causes problems with yield and purity.
Besides sensitivity of extraction, costs are a factor to be considered when selecting an appropriate extraction protocol for a laboratory. The costs per extraction are 1.95 Euro for the Chemagic DNA/RNA kit, 1.86 Euro for the QIAamp DNA Blood Mini kit, and 2.52 Euro for the QIAamp Viral RNA Mini kit. These costs make the Chemagen protocol a competitive candidate for laboratories extracting DNA and RNA. A further advantage of the product is that simultaneous extraction of both species of nucleic acids can be performed in the same time as the reference protocols. Specimens to be analyzed for both viral DNA and RNA have to be extracted only once. Therefore, hands-on time is minimized, and efficient use of specimens difficult to obtain, e.g., ascites, is guaranteed.
With the novel Chemagic DNA/RNA kit a very competitive new product is available. The analytical and clinical sensitivity are equal to those of the reference protocols. The simultaneous extraction of DNA and RNA and the underlying magnetic beads technology make it an interesting system for manual extraction of nucleic acids in a routine diagnostic laboratory and especially for automated extraction of nucleic acids. Very recently, an extraction robot using the Chemagic DNA/RNA kit in a 96-well format with high efficiency of extraction and minimization of cross contamination in preliminary experiments has been released. 
